Cross-talk between G protein-coupled receptors and protein tyrosine kinases is well-established, but the phenotypic consequences of these signaling interactions are not completely understood.
INTRODUCTION
selectively amplifies activation of phospholipase C and Ca 2+ signaling by endothelin-1 in fibroblasts (Mattingly et al., 1992) . Despite the apparent importance of endothelin-1 receptorSrc cross-talk in cell signaling, the ability of Src to participate in mitogenic signaling by endothelin-1 remains unclear.
In this study, we investigated whether Src or other Src family kinases participate in signaling cascades linking G protein-coupled endothelin-1 receptors to DNA synthesis and cell proliferation in mesangial cells, an important vascular target cell for endothelin-1 in vivo (Sorokin and Kohan, 2003) . We report here that endothelin-1-stimulated cell growth is blocked by a dominant negative Src mutant, by COOH-terminal Src kinase (Csk), by a pharmacologic Src antagonist, and by siRNA knockdown of Src. Moreover, Src activity was required for induction of the cyclin D1 protein in cells treated with endothelin-1. The findings emphasize the importance of cross-talk between endothelin-1 receptors and Src in propagating signals that regulate cell cycle progression. (DMEM, Gibco-BRL, 11885) supplemented with 17% fetal bovine serum (FBS), 100 U/ml penicillin, 100 µg/ml streptomycin, 5 ng/ml selenite, and 5 µg/ml each of insulin and transferrin in a CO 2 incubator at 37 0 C in the presence of 5% CO 2 . Characterization was performed by phase contrast microscopy and by immunostaining for intermediate filaments and surface antigens as described previously (Schultz et al., 1988) . Briefly, cells were positive for desmin, vimentin, and myosin, but did not stain for factor VIII, keratin, or common leukocyte antigen.
MATERIALS AND METHODS

Reagents
Measurements of DNA Synthesis in Transiently Transfected Cells:
To study the role of Src in endothelin-1-stimulated DNA-synthesis, mesangial cells in 6-well plates were transfected and the cells successfully transfected were identified by staining for β-galactosidase as described previously Wang et al., 2003) . Cells were transfected with 0.1 µg pRSVβGal and with 2 µg of the following plasmids as described (Simonson et al., 1996b) :
pSrcK-, SrcK+, pCMVCsk, pMv-Src, v-Ha-Ras. Incorporation of 5-bromo-2-deoxyuridine (BrdU, Sigma) into newly synthesized DNA in transiently transfected cells (i.e., β-galactosidase This article has not been copyedited and formatted. The final version may differ from this version. positive cells) was also assessed exactly as previously described Wang et al., 2003) . Briefly, after transfection cells were labeled for 24 h with 20 µM BrdU, monolayers were then washed twice with ice-cold DPBS and fixed for 5 min on ice with 2.0% formaldehyde/0.2% glutaraldehyde in DPBS. Cells expressing β-galactosidase were detected by histochemical analysis Wang et al., 2003) . Under these conditions 3-5 % of mesangial cells were transfected (i.e., β-galactosidase positive). BrdU incorporation into DNA was then identified by immunocytochemistry using 6 µg IgG/ml of a specific monoclonal antibody (Roche Applied Sciences, IN) as described previously Wang et al., 2003) . Cells were visualized under bright-field microscopy (Nikon Diaphot) with a neutral filter. Red cells (i.e., β-galactosidase positive) with dark nuclei (BrdU-positive) and light nuclei the Chi-squared test using InStat for Macintosh (GraphPad, San Diego, CA).
Measurement of BrdU Incorporation in Cells Treated with PP2 or PP3:
To study the effect of a pharmacological Src inhibitor on endothelin-1-induced DNA synthesis, cells were plated in 6 well plates. Cells, serum starved for 24 h in DMEM-0.5% FBS for 24, were pretreated with 10 µM of PP2 or PP3 for 1h before adding either 100 nM of endothelin-1 or 20% FBS. Cells were fixed and stained for BrdU incorporation as described above.
Western Blotting: Western blotting for PTyrSrc(416) and cyclin D1 in HMC was performed as previously reported by us with minor modifications (Mishra et al., 2003) . Briefly, cells were This article has not been copyedited and formatted. The final version may differ from this version. washed with ice cold PBS and scraped in CHAPS extraction buffer (50 mM Pipes/HCI, pH 6.5, 2 mM EDTA, 0.1% Chaps, 20 µg/ml leupeptin, 10 µg/ml pepstatin A, 10 µg/ml aprotinin, 5mM
DTT, 2mM Na pyrophosphate, 1mM Na 3 VO 4 , and 1mM NaF). An aliquot was saved for protein determination using the DC assay (Biorad, Hercules, CA). An equal volume of 2X SDS sample buffer was immediately added to the extraction buffer, and Western blotting was carried out using antibodies for human pTyr416Src, or cyclin D1. The membranes were reprobed for either total Src or β-actin to confirm equal protein loading. As previously described (Mishra et al., 2004) , the Western blots were analyzed by densitometry in NIH Image by normalizing values for the relevant protein to the highest value within each experiments (maximum level = 1).
siRNA-Mediated Src Gene Knockdown by RNAi:
A pool of four complementary siRNA oligonucleotide duplexes targeted specifically to human Src (GenBank NM_005417) and designed to leave 2 bp overhangs were obtained from Dharmacon Inc. Lafayette, CO (Cat. # M-003175). The algorithms for determining the siRNA sequences have been described in detail (Reynolds et al., 2004) . The siRNAs were introduced into mesangial cells with Lipofectamine 2000 (Invitrogen), according to the manufacturer's instructions. To determine the most effective dose of siRNA in mesangial cells, transfection was carried out with increasing concentrations of siRNA from 0-50 nM. Briefly, mesangial cells were plated at 50-70% density in 35 mm petri dishes a day prior to transfection. Cells were incubated with siRNA duplexes at final concentrations ranging from 2.5 to 50 nM in 2 ml of low serum containing OPTI-MEMI (5%FBS) for 18h. After the incubation with siRNAs in low serum medium, the level of serum was adjusted to that in complete medium and cells were grown for 48 h. 
RESULTS
We used cultured human mesangial cells to investigate the potential role of Src in mitogenic signaling by endothelin-1. Mesangial cells derive from the glomerular microvasculature where endothelin-1 participates in the compensatory growth of mesangial cells and remodeling of the glomerular capillaries following renal injury (Sorokin and Kohan, 2003) .
We previously showed that ET A G protein-coupled receptors stimulate Src activity and tyrosine phosphorylation in these cells (Simonson and Herman, 1993; Simonson and Rooney, 1994; Simonson et al., 1996a) . In addition, Src is required for induction of c-fos by endothelin-1 in mesangial cells (Simonson et al., 1996b) . Using an activation state-specific antibody against PTyr416 Src, we found that endothelin-1 induced a rapid and robust activation of Src in human mesangial cells (Fig. 1A,B) . Maximal Src activation occurred at 10 min and declined slowly thereafter ( Fig 1B) . These results suggest that the cell signaling pathways linking endothelin-1 receptors to putative long-term events such as cell proliferation are intact in mesangial cells and might involve Src protein tyrosine kinases.
To determine whether Src contributes to mitogenic signaling by endothelin-1, we first employed a dominant negative mutant strategy. A kinase-inactivating mutation in Src (Lys295 to Met, SrcK-) forms a dominant negative Src protein, which effectively blocks signaling by some but not all growth factor receptors in NIH 3T3 fibroblasts. Using a transient transfection assay to identify the effects of transfected genes on DNA synthesis, endothelin-1 increased the percentage of cells with BrdU+ nuclei when added to cells with vector alone (Fig. 2A, (Herman and Simonson, 1995; Simonson et al., 1996b) . Second, the effects of dominant negative mutants should be reversible, and we showed that over-expression of v-Src reversed inhibition of endothelin-1-stimulated DNA synthesis by Src K- (Fig. 2B ). Collectively, these findings suggest that the dominant negative actions of Src K-are specific and that Src contributes to mitogenic signaling by endothelin-1 in mesangial cells.
Additional evidence that Src contributes to mitogenic signaling by endothelin-1 was obtained by transfecting cells with a vector encoding COOH-terminal Src kinase (Csk), which phosphorylates the COOH-terminal tyrosine in Src and in other Src-family kinases and inactivates the kinases by maintaining the repressed conformation (Bjorge et al., 2000) . Gene
targeting and other studies confirm that Csk negatively regulates Src activity in vivo (Bjorge et al., 2000) . In cells transfected with vector alone, endothelin-1 increased the number of BrdU+ nuclei ( Fig. 3A ,B, Con, 31.8%; ET-1 58.1%). Transfection with Csk attenuated the endothelin-1-stimulated increase in BrdU+ cells (Fig. 3B , Con, 30.1%; ET-1 36.5%). Csk partially inhibited the mitogenic response to FBS but had no effect on DNA synthesis in cells transfected with vRas ( Fig. 3B ). Taken together, these results with Csk support the hypothesis that Src or other Src family kinases contribute to mitogenic signaling by endothelin-1.
To obtain independent evidence that Src contributes to mitogenic signaling by endothelin-1, we used a selective pharmacological antagonist of Src, PP2, and its inactive analog PP3 (Hanke et al., 1996) . In the presence of PP3, ET-1 stimulated a 1.7-fold increase in BrdU+ nuclei (Fig. 4 , Con 31.9%; endothelin-1 55.1%). However, consistent with a role for Src, PP2
This article has not been copyedited and formatted. The final version may differ from this version. completely prevented the increase in BrdU+ cells when endothelin-1 was added (Fig. 4 , Con 30.4%; endothelin-1 33.1%). PP2 had no effect on the increase in BrdU+ nuclei in cells treated with FBS, which suggested that PP2 did not non-specifically inhibit DNA synthesis (Fig. 4) .
One potential difficulty in interpreting the studies described above is that SrcK-, Csk, and PP2 might significantly block the activity of other Src family kinases due to the structural homology between members of the Src family. We therefore turned to RNA interference to knockdown the Src gene and determine the effect of on-target and off-target siRNAs for human Src on cell growth stimulated by ET-1. Forty-eight hours after transfection with a pool of four siRNA complexes specifically directed against human Src, total Src protein was significantly reduced by 5 nM of the siRNA complexes, and concentrations from 10 -50 nM effectively knocked-down Src protein below detectable levels by Western blotting (Fig. 5A ). As controls for specificity of Src knockdown, we note that the level of β-actin protein was unaffected by the on-target Src siRNAs, with suggests that the siRNA complexes as these low concentrations did not induce an interferon response that generally blocks protein synthesis. Addition of nontargeting siRNA complexes at 20 and 50 nM did not reduce total Src or β-actin levels (Fig. 5A ).
The specific and robust reduction of Src protein by siRNAs at 48 h provides a reliable basis for analyzing the role of Src in mitogenic signaling by ET-1.
Endothelin-1 was added 72 h after mock transfection or transfection with the Src siRNAs, and cell counts were measured thereafter at 24 and 48 h (Fig. 5B) . When added to mock transfected cells, endothelin-1 stimulated a time-dependent increase of cell number at 24 and 48 h (Fig. 5C ). In contrast, addition of endothelin-1 to cells transfected with Src siRNAs failed to increase cell number (Fig. 5C ). These results are consistent with our previous genetic and
This article has not been copyedited and formatted. The final version may differ from this version. In pathological remodeling of the glomerulus, mesangial cells are exposed to multiple mitogens in addition to endothelin-1 including platelet-derived growth factor (PDGF) (Haas et al., 1999) . We therefore asked whether the role of Src in mitogenic signaling was restricted to G protein-coupled receptors or whether Src also participates in mitogenic signaling by the PDGF Importantly, DNA synthesis in response to addition of both mitogens was effectively blocked by transfection with SrcK- (Fig. 6C) . These results are consistent with the idea that both PDGF and endothelin-1 utilize Src in mitogenic signaling in mesangial cells and that Src is required even when both mitogens were present simultaneously.
To better understand the mechanisms by which a Src-based endothelin-1 signal results in cell cycle progression, we asked whether Src is required for stimulation of cyclinD1 synthesis by endothelin-1. Transcriptional up-regulation of D-type cyclins occurs in G1, when they associate with and activate CDK4 or CDK6 to promote cell cycle progression. Endothelin-1 stimulated a
This article has not been copyedited and formatted. The final version may differ from this version. 3.7-fold increase in cyclinD1 protein after 4 h and a 8.3-fold increase after 24 h (Fig. 7A,C) .
Pretreatment with the pharmacological Src inhibitor PP2 attenuated the increase in cyclinD1
protein at 4, 8, and 24 h in cells treated with endothelin-1 (Fig. 7A,B) . We also confirmed that PP2 attenuated the endothelin-1-stimulated increase in PTyr416 Src (Fig. 7A,C) . The inactive Src antagonist, PP3, had no effect on endothelin-1-stimulated cyclinD1 protein (data not shown).
These results suggest that Src activation is required for endothelin-1 stimulation of cyclinD1, which in turn contributes to cell cycle progression in mesangial cells.
We next asked whether protein kinase C (PKC), an important effector of ET-1 signaling, also contributed to cyclinD1 induction by ET-1 in mesangial cells. The elevation of cyclinD1
protein by ET-1 in mesangial cells was markedly attenuated by BIS, a selective inhibitor of conventional type PKCs (Fig. 8A,B) . In addition, BIS blocked mesangial cell proliferation in response to ET-1 (Fig. 8C) . BIS alone had no effect on mesangial cell growth. Taken together, these results suggest that PKC is also required for induction of cyclinD1 by ET-1. To determine the relationship between PKC and Src in the ET-1 signaling pathway, we asked whether inhibition of PKC would block activation of Src by ET-1. In fact, preincubation with BIS completely prevented Src activation by ET-1 (Fig. 9A, B) . To demonstrate that BIS prevented activation of Src by PKCs, we also showed that BIS prevented Src activation by the phorbol ester TPA (Fig. 9C) . These results suggest that PKC is upstream of Src in the ET-1 signaling pathway.
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DISCUSSION
The G protein-coupled endothelin-1 receptors evoke signaling cascades leading to cell cycle progression and cell growth (Sorokin and Kohan, 2003) . Previous studies have shown that endothelin-1 receptors activate non-receptor protein tyrosine kinases such as Src, Pyk2, and focal adhesion kinase (Sorokin and Kohan, 2003) , but the role of specific non-receptor protein tyrosine kinases in mitogenic signaling by endothelin-1 has not been extensively studied. The goal of the present study was to determine if Src or Src-family kinases contribute to mitogenic signaling by endothelin-1 in human mesangial cells. Our results, based on independent genetic and pharmacological approaches to antagonize Src activity, strongly suggest that Src participates in a pathway that propagates signals from endothelin-1 receptors to elements of the cell cycle regulatory machinery that promote proliferation. Src or closely related Src-family kinases appear to participate in a pathway specifically linking endothelin-1 to induction of the cyclinD1 gene, an important regulatory step increasing CDK activity and cell cycle progression.
Src Kinase and Mitogenic Signaling by endothelin-1:
We have previously shown that endothelin-1 increases Src activity in mesangial and other cell types (Simonson and Herman, 1993; Simonson et al., 1996a ). An additional rationale for this study was that Src participates in ET-1-directed signaling events that might be linked to mitogenesis such as induction of the c-fos transcription factor (Simonson et al., 1996b) ; in addition, Schieffer and coworkers have previously shown that electroporation of Src-neutralizing antibodies in vascular smooth muscle cells blocks proliferation induced by ET-1 (Schieffer et al., 1997 Another observation that supports a role for Src in mitogenic signaling by endothelin-1 is that PP2 but not PP3 effectively prevents DNA synthesis in cells exposed to endothelin-1. PP2
is a selective inhibitor of Src-family kinases that binds to Thr338 in c-Src and prevents derepression of the inactive conformation. PP2 prevented endothelin-1-stimulated DNA synthesis at concentrations that have minimal effects on other types of protein tyrosine kinases such as cAbl and the epidermal growth factor receptor (Hanke et al., 1996) . Furthermore, the finding that PP3, which is almost structurally identical to PP2 but lacks significant Src inhibition, failed to block endothelin-1-stimulated DNA synthesis suggest that the inhibition by PP2 was related to its Src inhibitory properties.
One potential problem in interpreting these results is that SrcK-, Csk, and PP2 can inhibit other closely related members of the Src family such as Fyn and Lyk. Mesangial cells express
This article has not been copyedited and formatted. The final version may differ from this version. were made quiescent and then treated with endothelin-1, the proliferative response was inhibited, consistent with an essential role for Src in mitogenic signaling. We note that 20 nM of the Src siRNAs did not reduce β-actin levels, as would be expected in the siRNA induced a non-specific, interferon type of response that could globally block mRNA translation. Further evidence for a specific, on-target effect of the Src siRNAs was that identical concentrations of an off-target siRNA, which according to bioinformatic criteria has at least 4 mismatches to any known human gene (including Src-family genes) and which at 20 nM did not significantly alter the expression of human genes analyzed globally by microarray (personal communication, Dharmacon), did not reduce total Src or β-actin levels. This off-target siRNA also interacts with the RNA-induced silencing complex (RISC) and so serves as an important negative control for any non-specific but RISC-dependent gene silencing effects. Thus the results with Src siRNA provide strong support for the hypothesis that Src participates in mitogenic signaling by endothelin-1. and CDK6, they help drive cells through G1 into S phase (Obaya and Sedivy, 2002) . The importance of cyclinD1 regulation by ET-1 derives in part from the fact that D-type cyclins are rate-limiting for the formation of active Cdk4 and Cdk6 complexes (Obaya and Sedivy, 2002) .
Induction of CyclinD1 by an endothelin-1/Src-Based Signaling
In addition, induction of cyclinD1 was previously shown to be necessary for endothelin-1-induced proliferation in mesangial cells (Terada et al., 1998) Using pharmacological inhibition of Src, we showed that endothelin-1-stimulated Src activity is essential for increasing the level of cyclinD1 in mesangial cells. Endothelin-1 stimulated a robust increase in cyclinD1 protein, which was essentially abolished by preincubation with PP2 but not with the inactive PP3. Under the same conditions, we confirmed that PP2 greatly reduced PTyr 416 phosphorylation of Src. Taken together, these results provide strong support for the endothelin-1/Src-based signaling pathway in elevating cyclinD1 in mesangial cells and promoting cell cycle progression through G1 into S phase. A previous study in NIH3T3 cells reported that the PKC inhibitor calphostin C failed to block cyclin D1 induction by endothelin-1 (Suzuki et al., 1999) . In contrast, our results suggest that PKC plays an This article has not been copyedited and formatted. The final version may differ from this version. (Suzuki et al., 1999) and our data in mesangial cells is not immediately apparent but might result from the use of different PKC inhibitors or a cell type-specific difference in PKC-cyclin D1 signaling in mesangial cells versus NIH3T3 cells. Although we did not specifically test the putative role of the Ras-MAPK pathway in cyclinD1 induction, previous work has convincingly linked this pathway to induction of Dtype cyclins in a variety of cell types (Obaya and Sedivy, 2002) , and we have previously shown that Src functions upstream of Ras in mesangial cells (Herman and Simonson, 1995; Simonson et al., 1996b) . In fact, ERK activity is required for induction of cyclinD1 and for DNA synthesis in many cell types. It seems likely, therefore, that the endothelin-1/Src-based signal induces cyclinD1 by a Ras-MAPK pathway, although additional experiments are required to prove this hypothesis.
In summary, our results provide support for the importance of an endothelin-1/Src-based signaling cascade in DNA synthesis and cell cycle progression in mesangial cells. By extension, it seems likely that endothelin-1/Src-based signaling contributes to growth and compensatory remodeling of vascular and myocardial cells in vivo, which has been implicated in fibroproliferative response of these cells to injury (Amiri et al., 2004; Miyauchi and Masaki, 1999; Remuzzi et al., 2002) . Finally, these results point to a widening role for non-receptor protein tyrosine kinases in propagating mitogenic signals from G protein-coupled receptors.
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